Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $148 from $90 and keeps a Buy rating on the shares. The firm said 3Q25 earnings was uneventful as everything is on track: top-line Ph2 CVM data is expected in mid-December and top-line Ph3 MLM data in 1Q26. Canaccord said the bigger news was announcement of a new product candidate; QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis (DSAP).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Buy Rating Affirmed for Palvella Therapeutics: QTORIN Platform Expansion and Potential FDA Approval Drive Optimism
- Palvella Therapeutics Expands Rare Disease Pipeline
- Palvella Therapeutics: Strong Financial Position and Promising Clinical Trials Drive Buy Rating
- Promising Clinical Developments and Stable Financials Drive Buy Rating for Palvella Therapeutics
- Palvella Therapeutics price target raised to $120 from $100 at Oppenheimer